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Sirs: Sarcoidosis is a systemic,
granulomatous disorder of un-
known origin, rarely affecting the
nervous system [1]. There are pa-
tients with chronic disease whose
course is progressive while on ther-
apy with corticosteroids and im-
munosuppressive medicaments [2].
Several lines of evidence indicate
that tumor-necrosis factor-α (TNF-
α) plays a key role in the inflam-
matory process of some human au-
toimmune diseases [3]. Infliximab,
a chimeric monoclonal human-
murine IgG antibody directed
specifically against TNF-α, has
proved effective not only in refrac-
tory rheumatoid arthritis and
Crohn’s disease, but also in sys-
temic sarcoidosis [4, 5]. We report a
case of neurosarcoidosis refractory
to previous treatments in which in-
fliximab was associated with a
markedly improved clinical out-
come.
In April 2001 a 45-year-old man
developed slowly progressive
numbness and paresthesia of the
feet, ascending to the knee, erectile
dysfunction and adynamia. Un-
steadiness in walking and pares-
thesia of the hands followed
rapidly. Examination in October
2001 showed signs of a right
vestibulo-cochlear dysfunction to-
gether with distally pronounced
sensory disturbances of the lower
extremities and gait ataxia.
Laboratory investigations dis-
closed a hypogonadotropic hypo-
gonadism. The cerebrospinal fluid
analysis revealed an elevated pro-
tein level of 4344 mg/L (normal
180–480 mg/L), a lymphocytosis of
47x106/L (< 4.7x106/L) and an ele-
vated serum angiotensin-convert-
ing enzyme of 8 U/L (< 3 U/L).
Nerve conduction studies indicated
a demyelinating, sensorimotor
polyneuropathy of the upper and
lower extremities. MRI of the brain
revealed a prominent infundibu-
lum with homogeneous gadolin-
ium-enhancement. MRI of the lum-
bar spinal cord showed no
pathology. Computed tomography
of the chest disclosed bilateral hilar
and mediastinal lymphadenopathy
with normal lung parenchyma.
Biopsy findings of a hilar lymph
node were consistent with sar-
coidosis.
The patient was treated with
oral prednisone 50 mg daily, lead-
ing to an about 50 % regression of
the sensory symptoms within 3
months. Because of a Cushing’s
syndrome, associated with osteope-
nia, azathioprine (200 mg/day) was
initiated in February 2002 in con-
junction with prednisone taper to
10 mg/day.
Three months later the patient
developed a subacute conus-syn-
drome with an arachnoiditis at the
conus-cauda level (Fig.). Adminis-
tration of intravenous methylpred-
nisolone (500 mg/day for 3 days),
followed by augmentation of pred-
nisone to 20 mg/day was without
effect. Over the next 6 months the
sensory disturbances, the vertigo
and the unsteadiness in walking
progressed.
Because of the continuous dete-
rioration of the neurological condi-
tion while on immunosuppressive
therapy, infliximab (500 mg,
5 mg/kg of body weight) was ad-
ministered intravenously in Febru-
ary 2003 in conjunction with aza-
thioprine taper to 50 mg/day.
Infliximab was given again at 2, 8,
14, 20 and 26 weeks without ad-
verse effects. A few days after the
first dose the numbness of the feet
and the fatigue diminished, fol-
lowed within weeks by regression
of the gait ataxia and within
months by regression of the auto-
nomic dysfunctions.
Examination in September
2003, after 6 infliximab applica-
tions, showed diminution of the
right vestibulo-cochlear dysfunc-
tion, the spinal cord symptoms
and the gait ataxia. The distally
pronounced sensory disturbances
of the lower extremities were simi-
lar to those at the onset of the dis-
ease. MRI of the lumbar spinal
cord and the brain disclosed com-
plete resolution of the lesions
(Fig.) and cerebrospinal fluid
analysis showed a normalization of
the cell number (3x106/L) and a
decrease of the protein level to
904 mg/L. Nerve conduction stud-
ies showed no significant improve-
ment compared to baseline.
Our patient presented with a
biopsy-proven progressive neu-
rosarcoidosis, involving the hy-
pophysis, the right vestibulo-
cochlear nerve, the spinal cord and
the peripheral nervous system, re-
fractory to corticosteroids and aza-
thioprine. He experienced a re-
markable clinical improvement
with infliximab. There were no ad-
verse effects associated with inflix-
imab. Our findings are consistent
with two recent case reports in
which infliximab proved effective
for patients with refractory neu-
rosarcoidosis [6, 7].
LETTER TO THE EDITORS
JO
N
 1
43
2
761
References
1. Lower EE, Broderick JP, Brott TG,
Baughman RP (1997) Diagnosis and
management of neurological sarcoido-
sis. Arch Intern Med 157:1864–1868
2. Zajicek JP, Scolding NJ, Foster O,
Rovaris M, Evanson J, Moseley IF, et al.
(1999) Central nervous system sar-
coidosis–diagnosis and management.
QJ Med 92:103–117
3. Andreakos ET, Foxwell BM, Brennan
FM, Maini RN, Feldmann M (2002) Cy-
tokines and anti-cytokine biologicals in
autoimmunity: present and future. Cy-
tokine Growth Factor Rev 13:299–313
4. Baughman RP, Lower EE (2001) Inflix-
imab for refractory sarcoidosis. Sar-
coidosis Vasc Diffuse Lung Dis 18:70–74
5. Yee AM, Pochapin MB (2001) Treatment
of complicated sarcoidosis with inflix-
imab anti-tumor necrosis factor-alpha
therapy. Ann Intern Med 135:27–31
6. Pettersen JA, Zochodne DW, Bell RB,
Martin L, Hill MD (2002) Refractory
neurosarcoidosis responding to inflix-
imab. Neurology 59:1660–1661
7. Katz JM, Bruno MK, Winterkorn JM,
Nealon N (2003) The pathogenesis and
treatment of optic disc swelling in neu-
rosarcoidosis: a unique therapeutic re-
sponse to infliximab. Arch Neurol
60:426–430
M. Sollberger () · F. Fluri · T. Baumann ·
A. J. Steck
Department of Neurology
University Hospital
Petersgraben 4
4031 Basel, Switzerland
Tel.: +41-61/265-5431
Fax: +41-61/265-4491
E-Mail: marcsollberger@hotmail.com
S. Sonnet
Department of Neuroradiology
University Hospital
Petersgraben 4
4031 Basel, Switzerland
M. Tamm · M. Brutsche
Department of Pneumology
University Hospital
Petersgraben 4
4031 Basel, SwitzerlandFig. Initial and post-treatment MRI-studies: Sagittal T2 weighted (A) and contrast-enhanced T1 weighted (B)
MRI of lumbar spine before treatment show nodular hypointense, contrast-enhanced leptomeningeal lesions
surrounding conus and cauda equina with enlargement at the conus-cauda level. Post-treatment sagittal T2
weighted (C) and contrast-enhanced T1 weighted (D) MRI of lumbar spine show complete remission of the le-
sions with normal appearance of the conus and cauda equina.
